JO3564B1 - ببتيدات وتركيبات لعلاج ضرر المفاصل - Google Patents

ببتيدات وتركيبات لعلاج ضرر المفاصل

Info

Publication number
JO3564B1
JO3564B1 JOP/2014/0076A JOP20140076A JO3564B1 JO 3564 B1 JO3564 B1 JO 3564B1 JO P20140076 A JOP20140076 A JO P20140076A JO 3564 B1 JO3564 B1 JO 3564B1
Authority
JO
Jordan
Prior art keywords
formulations
peptides
joint damage
treat joint
treat
Prior art date
Application number
JOP/2014/0076A
Other languages
English (en)
Inventor
Shi Jian
Johnson Kristen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3564B1 publication Critical patent/JO3564B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

يقدم الاختراع الحالي عديد البيبتيدات جديدة مقاومة للبروتياز، بالاضافة إلى تركيبات و طرق لمعالجة أو تخفيف أو منع الحالات المتعلقة بتلف المفصل، متضمنة اصابة المفصل الحادة والتهاب خشونة المفاصل.
JOP/2014/0076A 2013-03-08 2014-03-06 ببتيدات وتركيبات لعلاج ضرر المفاصل JO3564B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10

Publications (1)

Publication Number Publication Date
JO3564B1 true JO3564B1 (ar) 2020-07-05

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0076A JO3564B1 (ar) 2013-03-08 2014-03-06 ببتيدات وتركيبات لعلاج ضرر المفاصل

Country Status (38)

Country Link
US (4) US9649359B2 (ar)
EP (2) EP3391900A1 (ar)
JP (3) JP6567429B2 (ar)
KR (1) KR102267341B1 (ar)
CN (2) CN105025917B (ar)
AP (1) AP2015008675A0 (ar)
AU (3) AU2014225348B2 (ar)
BR (2) BR112015021269B1 (ar)
CA (1) CA2903448C (ar)
CL (1) CL2015002443A1 (ar)
CO (1) CO7461145A2 (ar)
CR (2) CR20200290A (ar)
CU (1) CU24301B1 (ar)
CY (1) CY1120729T1 (ar)
DK (1) DK2964250T3 (ar)
EA (1) EA035158B1 (ar)
EC (1) ECSP15042898A (ar)
ES (1) ES2684349T3 (ar)
HR (1) HRP20181269T1 (ar)
HU (1) HUE038499T2 (ar)
IL (1) IL240727B (ar)
JO (1) JO3564B1 (ar)
LT (1) LT2964250T (ar)
MX (1) MX365157B (ar)
MY (1) MY173172A (ar)
NZ (1) NZ711037A (ar)
PE (1) PE20151528A1 (ar)
PH (1) PH12015501983B1 (ar)
PL (1) PL2964250T3 (ar)
PT (1) PT2964250T (ar)
RS (1) RS57446B1 (ar)
SG (1) SG11201506490TA (ar)
SI (1) SI2964250T1 (ar)
TN (1) TN2015000385A1 (ar)
TW (1) TWI634124B (ar)
UY (1) UY35368A (ar)
WO (1) WO2014138687A1 (ar)
ZA (1) ZA201505966B (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2018078706A1 (ja) 2016-10-24 2018-05-03 住友化学株式会社 セパレータ、およびセパレータを含む二次電池
ES2987020T3 (es) * 2016-11-09 2024-11-13 Icm Co Ltd Fragmento de Nkx3.2 y composición farmacéutica que lo comprende como ingrediente activo
JP2019535707A (ja) * 2016-11-14 2019-12-12 ノバルティス アーゲー 軟骨損傷および関節炎の処置のための方法および組成物
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
EP4346876A1 (en) 2021-05-24 2024-04-10 Novartis AG Methods for the treatment of osteoarthritis
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
WO2023084388A1 (en) 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2025169047A1 (en) 2024-02-05 2025-08-14 Novartis Ag Improved production of angptl3 mimetics

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO2000053757A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO1999058660A1 (en) 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP1198568B1 (en) 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
ATE456655T1 (de) 2000-10-16 2010-02-15 Genentech Inc Behandlungsverfahren unter verwendung von wisp- polypeptiden
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
EP1456360B1 (en) 2001-04-19 2015-06-03 The Scripps Research Institute Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
KR101012904B1 (ko) 2001-11-16 2011-02-08 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는조성물 및 이를 사용하는 방법
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
AU2003277373B2 (en) 2002-10-16 2009-05-07 The Scripps Research Institute Site specific incorporation of keto amino acids into proteins
SG160203A1 (en) 2002-10-16 2010-04-29 Scripps Research Inst Glycoprotein synthesis
CN101223272B (zh) 2003-04-17 2013-04-03 斯克利普斯研究院 扩展真核生物遗传密码
EP1704242A4 (en) 2003-07-07 2008-06-18 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
EP1658366A4 (en) 2003-07-07 2006-08-09 Scripps Research Inst COMPOSITIONS OF ORTHOGONAL GLUTAMYL-TRNA AND AMINOACYL-TRNA-SYNTHETASEPAARES AND THEIR USES
EP1649004A4 (en) 2003-07-07 2008-04-09 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LYSYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
ES2666693T3 (es) 2004-09-21 2018-05-07 The Scripps Research Institute Incorporación in vivo de alquinil aminoácidos a proteínas en eubacterias
EP1807515A4 (en) 2004-10-27 2008-06-18 Scripps Research Inst Orthogonal translation components for the in vivo incorporation of unnatural amino acids
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
EP1899457B1 (en) 2005-05-24 2012-09-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
AU2007223830A1 (en) 2006-03-09 2007-09-13 The Scripps Research Institute System for the expression of orthogonal translation components in eubacterial host cells
TWI419697B (zh) 2006-12-06 2013-12-21 Seikagaku Kogyo Co Ltd 治療關節失調之長效藥劑
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
AU2012212047A1 (en) 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage

Also Published As

Publication number Publication date
JP2016510763A (ja) 2016-04-11
JP2020015725A (ja) 2020-01-30
KR20150125712A (ko) 2015-11-09
CU20150097A7 (es) 2016-05-30
BR112015021269B1 (pt) 2023-04-11
CN105025917B (zh) 2020-08-18
ES2684349T3 (es) 2018-10-02
SG11201506490TA (en) 2015-09-29
EA035158B1 (ru) 2020-05-06
HRP20181269T1 (hr) 2018-10-19
HUE038499T2 (hu) 2018-10-29
EP2964250A1 (en) 2016-01-13
AU2016203028B2 (en) 2017-02-02
LT2964250T (lt) 2018-07-25
BR112015021269A2 (pt) 2017-10-10
JP6567429B2 (ja) 2019-08-28
US20200268849A1 (en) 2020-08-27
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
RS57446B1 (sr) 2018-09-28
CU24301B1 (es) 2017-12-08
US20170252407A1 (en) 2017-09-07
EA201591661A1 (ru) 2015-12-30
CA2903448C (en) 2021-03-23
US20160008433A1 (en) 2016-01-14
TN2015000385A1 (en) 2017-01-03
TW201444865A (zh) 2014-12-01
MX2015011963A (es) 2015-12-09
TWI634124B (zh) 2018-09-01
ZA201505966B (en) 2017-03-29
CL2015002443A1 (es) 2016-05-20
US10328126B2 (en) 2019-06-25
AU2016277608B2 (en) 2018-04-05
WO2014138687A1 (en) 2014-09-12
AU2016203028C1 (en) 2017-06-01
CA2903448A1 (en) 2014-09-12
AU2014225348B2 (en) 2016-03-31
AU2016203028A1 (en) 2016-05-26
KR102267341B1 (ko) 2021-06-21
CN111808182A (zh) 2020-10-23
CR20150466A (es) 2015-10-27
HK1214754A1 (en) 2016-08-05
PH12015501983A1 (en) 2016-01-11
NZ711037A (en) 2018-07-27
AU2014225348A1 (en) 2015-09-10
CO7461145A2 (es) 2015-11-30
AP2015008675A0 (en) 2015-08-31
CY1120729T1 (el) 2019-12-11
US20220184182A1 (en) 2022-06-16
AU2016277608A1 (en) 2017-01-12
PL2964250T3 (pl) 2018-10-31
JP2021178841A (ja) 2021-11-18
IL240727B (en) 2019-12-31
PT2964250T (pt) 2018-10-19
EP3391900A1 (en) 2018-10-24
MX365157B (es) 2019-05-24
CN105025917A (zh) 2015-11-04
CR20200290A (es) 2020-08-27
US9649359B2 (en) 2017-05-16
IL240727A0 (en) 2015-10-29
DK2964250T3 (da) 2018-08-06
UY35368A (es) 2014-10-31
ECSP15042898A (es) 2019-03-29
BR122016021558B1 (pt) 2023-03-28
MY173172A (en) 2020-01-02
EP2964250B1 (en) 2018-05-16
JP6918871B2 (ja) 2021-08-11
US11179442B2 (en) 2021-11-23
BR122016021558A2 (pt) 2019-07-30
PH12015501983B1 (en) 2020-09-25

Similar Documents

Publication Publication Date Title
JO3564B1 (ar) ببتيدات وتركيبات لعلاج ضرر المفاصل
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017006664A2 (pt) terapias de combinação
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
GB2541571A (en) Pharmaceutical compositions
LT3206497T (lt) Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201790380A1 (ru) Ингибиторы mk2 и их применения
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
MX373409B (es) Composiciones para fibras de queratina.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
EA201591709A1 (ru) 5-бром-индирубины
LT3110425T (lt) Nelaki oftalmologinė kompozicija, ypač sausų akių sindromui gydyti
EP3643297A4 (en) OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA
PL3582796T3 (pl) Kompozycja do leczenia kaszlu